Genetic modification of mammalian cells to confer resistance to CSF1R antagonists

US12421517B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• Mathew Blurton-Jones · Irvine, US
• Jean Paul Chadarevian · Irvine, US
• Robert Spitale · Irvine, US
• Sunil Gandhi · Irvine, US
• Whitney England · Irvine, US
• Hayk Davtyan · Irvine, US
• Jonathan Hasselmann · Irvine, US

Key dates

• Filing date: Dec 21, 2022
• Grant date: Sep 23, 2025
• Expiry date: Dec 21, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2506/45
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Microglia/monocytes exist within a ‘niche’ which limits the total number of microglia/monocytes/macrophages that reside within a mammalian central nervous system (CNS). Therefore, methods are needed that can help therapeutically modify microglia, monocytes, and macrophages or the cells that give rise to them to compete with endogenous microglia and partially or completely occupy the CNS niche. The present disclosure features therapeutic microglia, monocytes, or macrophages that have a selective advantage in comparison to endogenous brain resident microglia in their response to CSF1R inhibitors. Specifically, therapeutic cells developed in the present disclosure do not die at a given dose of CSF1R inhibitor that is sufficient to kill endogenous microglia. The therapeutic cells described herein can be used to treat neurological diseases.